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sRate and Predictability of Graft Rupture After Endovascular and Open
Abdominal Aortic Aneurysm Repair: Data From the EVAR Trials
Wyss TR, Brown LC, Powell JT, et al. Ann Surg 2010;252:805-12.
Conclusion: There are no ruptures after open repair for abdominal
aortic aneurysm (AAA) and a low rate of rupture after endovascular aneu-
rysm repair (EVAR). Mortality after graft rupture is high. Few ruptures after
EVAR are spontaneous, with most having had complications identified
during surveillance.
Summary: Aneurysm rupture after EVAR is well recognized, and
endograft rupture has high mortality (Schlosser FJV, Eur J Vas Endovasc
Surg 2009;37:15-22). Graft-related complications after EVAR are frequent.
Certain types of endograft complications (endoleak types I and III, stent
graft disintegration and migration) increase the risk of aneurysm rupture
(Fransen GA, Eur J Vas Endovasc Surg 2003;26:487-93). The authors
analyzed the patients in the United Kingdom (UK) EVAR trials to assess the
rate and factors associated with rupture after EVAR or open repair of AAA.
Up to July 2009, 848 elective EVARS and 594 elective open AAA
repairs had been performed in the UK EVAR Trials 1 and 2. Patients were
followed-up for complications, reinterventions, and rupture. Incidence of
rupture was analyzed with respect to baseline anatomy and subsequent
complications in a Cox regression analysis model.
No ruptures occurred in patients treated with open repair, but 27
ruptures occurred after EVAR during a mean follow-up of 4.8 years, for a
crude rate of 0.7 ruptures/100 person-years (95% CI, 0.5-1.0). Of patients
who developed endograft rupture, 67% died 30 days of rupture. Five
ruptures occurred in the first 30 postoperative days and 22 after that; crude
rates of rupture were 7.2 (95% CI, 3.0-17.4) and 0.6/100 person-years
(95% CI, 0.4-0.9). Previous complications (endoleak type I, type II with sac
expansion, type III, migration or kinking) increased the risk of rupture, with
a hazard ratio of 8.83 (95% CI, 3.76-20.76; P  .0001).
Comment: EVAR is a form of management of AAA and not a cure for
AAA. As such, patients must be continually monitored for complications
associated with potential rupture of an endograft-managed AAA. Patients
with rupture fall into roughly three groups. Those who have a rupture in the
perioperative EVAR period likely reflect inadequate initial isolation of the
aneurysm. A small group of patients rupture with reasonable compliance
with recommended surveillance. This suggests complications associated
with EVAR that occur after a negative surveillance study can rapidly lead to
rupture. Most ruptures, however, occur in patients with an identified prob-
lem with their endograft. Sac expansion was documented in 15 of 17 in this
group. Rupture after EVAR can be minimized by ensuring that before
leaving the hospital, the patients have had technically satisfactory procedures
and that sac expansion is evaluated, diagnosed, and aggressively treated.
Aspirin for Prevention of Cardiovascular Events in a General Popula-
tion Screened for a Low Ankle Brachial Index: A Randomized Con-
trolled Trial
Fowkes FG, Price JF, Stewart MCW, and the Aspirin for Asymptomatic
Atherosclerosis Trialists. JAMA 2010;303:841-8.
Conclusion: Patients with asymptomatic vascular disease identified by
a low ankle-brachial index (ABI) do not have a reduction in vascular events
with daily aspirin administration.
Summary: A low ABI is a marker of systemic atherosclerosis and is
associated with coexisting cerebral vascular and coronary disease. In men
with a low ABI (0.9), there is a 27% risk over 10 years of a major coronary
event vs 9% in those with ABIs between 1.11 and 1.4; for women, the figures
are 19% and 9% (Fowkes FG, JAMA 2008;300:197-208). It is controversial
whether screening ABIs should be performed in asymptomatic patients
because there is minimal evidence for an effective intervention in asymptom-
atic individuals with a low ABI (US Preventative Services Task Force,
AHRQ, Publication No. 05-0583-A-EF. http//www.ahrg.gov/clinic.usp-
stf05/pad/padrs.htm). The authors sought to determine the effectiveness
of aspirin in preventing cardiovascular events in otherwise asymptomatic
individuals found to have a low ABI. This was an intention-to-treat, double-
blind, randomized, controlled trial conducted between April 1998 and
October 2008 involving 28,980 men and women aged 50 to 75 years. All
were free of clinically evident vascular disease. Patients wre recruited from a
community health registry in Scotland and had ABI screening tests, and
3350 were identified with a low ABI (0.095) and entered the trial. Patients
were randomized to daily 100 mg enteric-coated aspirin or placebo. The
primary end point was a composite end point of an initial fatal or nonfatal
coronary event, a revascularization procedure, or stroke. Secondary end
points were a composite of all primary end point events plus new intermit-
t
o
1158ent claudication or transient ischemic attack. An additional secondary end
oint was all cause mortality.
Mean follow-up was 8.2  1.6 years. During follow-up, 357 of the
350 study participants had a primary end point event (13.5/1,000 person-
ears; 95% CI, 12.2-15.0). There was no statistical difference between the
ncidence of the primary end point between groups, consisting of 13.7
vents/1000 person years in the aspirin group vs 13.3 in the placebo group
HR, 1.03; 95% CI, 0.84-1.7). The secondary end point of any vascular
vent occurred in 578 participants (22.8/1,000 person years; 95% CI,
1.0-24.8). There was no statistical difference between the aspirin (22.8
vents/1000 person-years) and placebo (22.9 events/1000 person years)
roups (HR, 1.0; 95%CI, 0.85-1.17). Similarly there was no difference in all
ause mortality between groups (176 vs 186 deaths, respectively; HR, 0.95;
5% CI, 0.77-1.16). Major hemorrhage requiring admission to the hospital
ccurred in 34 subjects (2.5/1,000 person years in the aspirin group and
.5/1,000 person years in the placebo group; HR, 1.71; 95% CI, 0.99-
.97).
Comment: The trial suggested ABI screening in individuals free of
linical cardiovascular disease is unlikely to be beneficial if the intervention
or a low ABI is prophylactic low-dose aspirin. It does not rule out the
ossibility that other therapies, such as statins or perhaps different antiplate-
et agents with less hemorrhagic risk, might confer benefit. In practical
erms, the results indicate that somewhere between 500 and 600 people
ould need to be screened with ABI studies and treated with aspirin to
revent one major cardiovascular event over 8 years. It seems difficult to
ustify the resources required for such massive screening with such little
eturn.
ssociation Between Aneurysm Shoulder Stress and Abdominal Aortic
neurysm Expansion: A Longitudinal Follow-Up Study
i Z-Y, Sadat U, U-King-Im J, et al. Circulation 2010;122:1815-22.
Conclusion:High shoulder stress is associated with rapid expansion of
bdominal aortic aneurysm (AAA).
Summary: AAA rupture can be seen as an example of structural failure
hen mechanical stresses acting on a weakened aortic wall exceed local
echanical failure strength. Wall stress may be due to an influence of several
oncomitant factors, including aneurysm shape, biochemical composition of
he aneurysmwall, characteristic and shape of intraluminal thrombus, eccen-
ricity of the aneurysm, and interaction between solid domains and fluid.
hanges in wall stresses may be useful in identifying AAA stability. The
uthors sought to evaluate the association of wall stress and expansion rate of
AAs in a longitudinal follow-up study. The study included 44 patients with
n infrarenal AAA monitored in one university vascular center. Axial and
-dimensional computed tomography reconstruction images were used to
ssess maximum diameter of the aneurysm and location of the aneurysm
houlder at baseline and just before surgery. The shoulder of the aneurysm
as defined as the junction of the neck and the aneurysm sac. Maximum
iameter was defined as the maximum distance between the outer walls of
he aorta in the aneurysm sac. Distances of the two locations were measured
rom the renal artery. Patients were divided into two groups: those with
table AAAs, defined as an expansion rate of 0.4 cm/year, and those with
apidly expanding AAAs, defined as an expansion rate of 0.4 cm/year.
tructural analysis was performed to calculate wall stresses of AAAs at
aseline and follow-up visits. A nonlinear large-strain finite element method
as used to compute wall stress distribution.
Slowly and rapidly expanding AAAs had comparable baselinemaximum
iameters (median 4.35 cm [interquartile range, 4.12-5.0 cm] vs 4.6 cm
interquartile range, 4.2-5.0 cm]; P  .32). Rapidly expanding AAAs had
igher shoulder stresses than slowly expanding AAAs (median, 300 kPa
interquartile range, 280-320 kPa] vs 225 kPa [interquartile range, 211-249
Pa]; P  .0001). There was a significant correlation of 0.71 between
aseline shoulder stress and expansion rate (P  .0001).
Comment: The Society for Vascular Surgery uses AAA diameter as the
rimary criteria for determining follow-up intervals for unoperated AAAs. It
s known, however, that some small AAAs will rupture unpredictably.
xtending aneurysm surveillance to include measurement of shoulder stress
s well as aneurysm diameter may eventually allow the determination of
hich AAAs should be repaired at relatively smaller diameters and which
mall AAAs are more likely to exhibit more rapid expansion and should
herefore be monitored with closer follow-up intervals than currently rec-
mmended.
